Principal Financial Group Inc Amylyx Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$2.71 - $19.57 $525 - $3,796	194 Added 1.34%	14,666 $41,000
Q4 2023 Feb 07, 2024	BUY	$12.07 - $18.46 $1,520 - $2,325	126 Added 0.88%	14,472 $213,000
Q3 2023 Nov 02, 2023	SELL	$18.08 - $23.45 $6,002 - $7,785	-332 Reduced 2.26%	14,346 $262,000
Q2 2023 Aug 07, 2023	SELL	$20.98 - $31.42 $6,692 - $10,022	-319 Reduced 2.13%	14,678 $316,000
Q1 2023 May 09, 2023	BUY	$27.71 - $40.93 $41,121 - $60,740	1,484 Added 10.98%	14,997 $440,000
Q4 2022 Feb 09, 2023	BUY	$29.75 - $39.26 $402,011 - $530,520	13,513 New	13,513 $499,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.